header image

Page 49«..1020..48495051..6070..»

Incredible before and after videos of powerful healing …

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

AVON LAKE, Ohio The same stem cell treatments that have revolutionized human healthcare are now are giving elderly and injured pets a new leash on life.

How they come in and after the treatment is phenomenal, said Dr. Carmen Petti. Theyre not limping anymore, not lame anymore.

Dr. Petti is one of the first, and one of only a handful of veterinarians in Northeast Ohio performing the procedures.

The treatment has produced incredible results on some skin conditions, osteoarthritis, hip dysplasia, ligament damage and/or cartilage injuries.

Its also being tested on numerous other ailments and diseases.

She says, in one study, that followed 155 dogs they saw 99% improvement.

The procedure takes about 30 minutes, and begins with about two to three tablespoons of fat.

During the procedure, which takes about 30 minutes, doctors harvest two to three tablespoons of fat from the animal.

Dr. Petti says adipose tissue is loaded with high regenerative stem cells.

They get put under anesthesia and from there we make an incision in the abdomen, and we take fat thats right under the umbilical, said Dr. Petti. The fat then gets activated through a special process so stem cells are able to divide and become something else.

The stem cells are then re-injected in the problem joint or re-introduced through an IV.

Leftover or remaining stem cells are then sent to MediVet Biologics in Kentucky to be cryogenically stored until they are needed again for another treatment.

According to a spokesperson, MediVet is a global leader in veterinary regenerative medicine and biological solutions with a long history of helping animals using stem cells and groundbreaking procedures.

You know to see is to believe, said Dr. Petti.

But its not cheap.

Costs range from $1,000 up to $2,500 for the first procedure and surgery.

Subsequent injections are significantly lower because the animal doesnt have to be anesthetized.

I said no in the beginning; I said thats crazy, said Kima Yandell.

Kima and her husband, Brian, are the proud parents of a two-year-old hairless Sphinx cat named Kruze, who was diagnosed with hypertrophic cardiomyopathy or HCM.

HCM causes the heart muscle to thicken and is nearly always fatal.

Its such a horrible ending if it goes to fruition, said Brian Yandell. Obviously were upset about that.

Although HCM isnt currently an on label usage for the stem cell treatments, they say Kruze has responded amazingly well to the procedures.

The stem cells immediately had some effect, said Brian. Its like an immediately happier cat.

The Yandells are hopeful that more pet owners will get involved and, ultimately, bring down the costs for everyone over time.

But more than anything, they just want Kruze to have quality of life, and they say, right now thanks to his own stem cells he is a healthy, happy cat.

The futures bright, said Dr. Petti. I think stem cells are going to become a regular part of treatment protocols for everything: diabetes, kidney disease you name it.

Read more, here.

See original here:
Incredible before and after videos of powerful healing ...

Global Canine Stem Cell Therapy Market with (Covid-19) Impact Analysis: Future Development, Business Growth and Applications to 2025 – Cole of Duty

Researchstore.biz has released a new research report titled Global Canine Stem Cell Therapy Market 2020 by Company, Type and Application, Forecast to 2025 which offers a strategic evaluation of the market. The report presents prime parameters such as market size, revenue, sales analysis, and key drivers, and projection of the market by product, area, and use. The report delivers an in-depth analysis of the market with current and future trends. The report recognizes overall growth opportunities, industry drivers, obstacles, latest discoveries, and openings available for newcomers in the global Canine Stem Cell Therapy market.

Competitive Outlook:

The report further contains a competitive scenario of the major market players focusing on their sales revenue, customer demands, company profile, import/export scenario, business strategies that will help the emerging market segments in making major business decisions. In addition, their product portfolio, respective product applications, and product features have been emphasized in the report. The report also provides company shares and distribution shares data for the Canine Stem Cell Therapy market category and global corporate-level profiles of the key market participants.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/48453

NOTE: This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-dept analysis of Canine Stem Cell Therapy market.

The study profiles and examines leading companies and other prominent companies operating in the global Canine Stem Cell Therapy industry, covering: VETSTEM BIOPHARMA, VetMatrix, Aratana Therapeutics, Cell Therapy Sciences, Vetbiologics, Regeneus, ANIMAL CELL THERAPIES, Okyanos, Medivet Biologics, Magellan Stem Cells, Stemcellvet,

The far-reaching market study enlists a focused assessment of this business space and the regional landscape of this vertical. As per the report, the Canine Stem Cell Therapy market has established its presence across regions such as: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

On the basis of product, this report displays the production, revenue, price, market share, and growth rate of each type, primarily split into: Allogeneic Stem Cells, Autologous Stem cells

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share market growth rate for each application, including: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes

This search provides an analysis of indirect and direct sales channels, helps you to plan the right distribution strategy. The study also predicts the influence of different industry aspects on the global Canine Stem Cell Therapy market segments and regions. It delivers analysis on consumption volume, region-wise import/export analysis, and forecast Canine Stem Cell Therapy market from 2020-2025. At last, the report exhibits an analysis of leading marketing players, product specification, company profiles along with the contact details, production cost.

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-canine-stem-cell-therapy-market-2020-48453

Important Aspects of Canine Stem Cell Therapy Market Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.researchstore.biz

Here is the original post:
Global Canine Stem Cell Therapy Market with (Covid-19) Impact Analysis: Future Development, Business Growth and Applications to 2025 - Cole of Duty

Rise in Prevalence of Depression that Boosts the Growth of Canine Stem Cell Therapy Market In Industry – Personal Injury Bureau UK

The surging COVID-19 (Coronavirus) is anticipated to have a long-term impact on the Canine Stem Cell Therapy market. Hence, companies in the Canine Stem Cell Therapy market are increasing efforts to get a hands-on for the resources they can capitalize on to minimize the impending consequences of COVID-19. Companies can now avail our recently published reports with comprehensive analysis on COVID-19 and its impact on the global market.

Assessment of the Global Canine Stem Cell Therapy Market

The global Canine Stem Cell Therapy market report throws light on the reliable and credible insights related to the various segments and sub-segments of the market. The market study elaborates on the various factors that are projected to impact the overall dynamics of the global Canine Stem Cell Therapy market over the forecast period (20XX-20XX).

As per the report prepared by analysts of Market Research Reports Search Engine (MRRSE), the value of the Canine Stem Cell Therapy market was predicted to reach ~US$ XX in 20XX and attain a market value of ~US$ XX by the end of 20XX. Further, the study reveals that the market is slated to grow at a robust CAGR of XX% during the forecast period.

Request Sample Report @https://www.mrrse.com/sample/16152?source=atm

The market study aims to provide a competitive edge over other players in the Canine Stem Cell Therapy market:

The report splits the global Canine Stem Cell Therapy market into different market segments such as:

The region-wise segmentation offers critical information such as the market share, revenue analysis, and market attractiveness of each region.

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:

Application:

End User:

Region:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/16152?source=atm

Vital statistics enclosed in the report:

Buy This Report @ https://www.mrrse.com/checkout/16152?source=atm

Read the original here:
Rise in Prevalence of Depression that Boosts the Growth of Canine Stem Cell Therapy Market In Industry - Personal Injury Bureau UK

WEATHER NOW: Clouds And Fog Return Tonight Toggle header content – WPRI.com

RI rental assistance money stalledVideo / 20 hours ago

Data discrepancy explainedTarget 12 / 23 hours ago

Mount Pleasant students, teachers outraged over principals firingVideo / 2 days ago

Survey: Distance learning here to stay, snow days gone, attendance upVideo / 2 days ago

Computer attack targets Care New England hospital groupVideo / 3 days ago

Video Now: Care New England CEO on the IT security incidentVideo / 3 days ago

Cyber attack on Care New England raises questions over the safety of patients' personal informationVideo / 2 days ago

A matter of life and death: The next crisis facing Rhode Island is evictionsVideo / 3 days ago

VIDEO NOW: Gov. Raimondo's special request to local landlordsVideo / 1 week ago

Rhode Islanders struggling to get an appointment at the DMVVideo / 4 days ago

Neronha seeks more tools to investigate allegations of police misconductVideo / 4 days ago

RIC dean accused of retaliation after diversity discussion with instructorVideo / 1 week ago

Read more from the original source:
WEATHER NOW: Clouds And Fog Return Tonight Toggle header content - WPRI.com

Study: Tick Surveillance and Control Lagging in US – Lab Manager Magazine

While the prevalence of Lyme disease and other illnesses spread by ticks has steadily increased in the United States over the past 20 years, a new study of the state of American tick surveillance and control reveals an inconsistent and often under-supported patchwork of programs across the country. For instance, while about two-thirds of tick management programs engage in passive tick surveillance, such as accepting tick samples submitted by the public, only 46 percent engage in routine active tick surveillance, such as focused collection of tick samples in the field.

Northeast Regional Center for Excellence in Vector-Borne Diseases

ANNAPOLIS, MD June 17, 2020 While the prevalence of Lyme disease and other illnesses spread by ticks has steadily increased in the United States over the past 20 years, a new study of the state of American tick surveillance and control reveals an inconsistent and often under-supported patchwork of programs across the country.

Annually reported cases of tickborne disease more than doubled between 2004 and 2018, according to the US Centers for Disease Control and Prevention (CDC), while seven new tickborne germs were discovered in that same timeframe. But a clear gap exists in our public health infrastructure, say researchers who have conducted the first-ever survey of the nation's tick management programs.

The survey showed that less than half of public health and vector-control agencies engage in active tick surveillance, and only 12 percent directly conduct or otherwise support tick-control efforts. These and other findings from the survey, conducted by university researchers at the CDC's five Vector-Borne Disease Regional Centers of Excellence, were published June 17 in theJournal of Medical Entomology.

"Ticks are responsible for the majority of our vector-borne illnesses in the US, and our programming does not adequately meet the need in its current form, for both surveillance and control," says Emily M. Mader, MPH MPP, lead author on the study and program manager at the Northeast Regional Center for Excellence in Vector-Borne Diseases, housed at Cornell University.

Mader and colleagues surveyed 140 vector-borne disease professionals working at state, county, and local agencies in the fall of 2018 to learn about their program objectives and capabilities for tick surveillance and control, testing ticks for disease-causing germs, and barriers to success. Reaching even that many respondents proved challenging, as no central database of tick-management programs or contacts was available.

The blacklegged tick (Ixodes scapularis), shown here in multiple life stages suspended in a vial.

Northeast Regional Center for Excellence in Vector-Borne Diseases

Highlights from the survey of tick-management programs include:

Less than half of tick-management programs proactively collect ticks in their area. While about two-thirds of respondents (65 percent) said their programs engage in passive tick surveillance, such as accepting tick samples submitted by the public, only 46 percent said their programs engage in routine active tick surveillance, such as focused collection of tick samples within their community.

Only a quarter of tick-management programs test ticks for disease-causing germs. Just 26 percent of survey respondents said their jurisdiction conducts or financially supports testing of tick samples for disease-causing pathogens. And only seven percent said their programs work to evaluate the presence of such pathogens in the animal hosts (such as mice and other rodents) from which ticks acquire those pathogens in their area.

"Pathogen testing is an essential component of surveillance and is needed in order to understand tickborne disease risk to communities," says Mader. "There appears to be a significant barrier for many tick-surveillance programs across the country to access pathogen-testing services."

Capacity for public tick-control efforts is low. Only 12 percent of respondents said that their jurisdiction conducts or financially supports tick control, with those efforts primarily focused reducing tick presence on animal hosts (such as deer and rodents).

Mader says limited resources mean tick-management programs need reliable, proven control methods. "They are not going to invest in a strategy unless it has been investigated and shown to make a difference in reducing the burden of ticks and tickborne diseases," she says. "Right now, supporting this research is a major need. These kinds of evaluations often take at least three years to complete and require a significant investment."

Tick surveillance and control happen in a range of sectors. The most common employment sectors among respondents being public health, mosquito control, cooperative extension, and agriculture. And more than half of respondents (57 percent) said their programs work with academic partners to conduct tick surveillance.

"The world of ticks reaches entomologists, veterinarians, medical doctors, public health, natural resource managers, farmers, pet owners, scientists, and anyone that enjoys the outdoors," says Nohra Mateus-Pinilla, PhD, co-author on the study and director of the Veterinary Epidemiology Laboratory at the University of Illinois's Illinois Natural History Survey. "The partnerships stand out because broad, collaborative networks are paramount to a positive and productive path for the advancement of this field."

Info and data sharing on ticks and public health is lagging. Less than a quarter of respondents said their tick-management programs disseminate information to local health departments (23 percent) or report data to the CDC (14 percent).

Greater support for tick-management programs is critical. To improve tick-management programs, respondents commonly cited the need for stable funding, training for personnel, and standardized, research-based guidance and protocols.

Tick surveillance and control happen across a range of sectors, the most common being public health, mosquito control, cooperative extension, and agriculture. More than half of tick management programs also work with academic partners to conduct tick surveillance.

Northeast Regional Center for Excellence in Vector-Borne Diseases

In December 2019, the Kay Hagan Tick Act was signed into federal law, authorizing $150 million to strengthen various aspects of the nation's efforts to vector-borne disease, including reauthorization of the CDC's Vector-Borne Disease Regional Centers of Excellence for an additional five years, through 2026. The CDC also issued guidance documents in late 2018 and early 2020 to provide tick-management programs with best practices for surveillance of blacklegged tick species (Ixodes scapularis and Ixodes pacificus) and other hard tick species across the US.

These steps address needs revealed in the survey of tick-management programs, and Mader and Mateus-Pinilla say the survey will serve as an important baseline from which to measure future progress and improvement.

"Overall, tick-work demands a long-term commitment. Ticks can take years to complete their life cycle, use different hosts to move around, and take advantage of weather and habitat changes," says Mateus-Pinilla. "As such, research on these vectors requires long-term and sustained commitment to research, surveillance, and partnerships across a broad range of disciplines, health professionals, and the public."

- This press release was originally published onEntomology Today, the Entomological Society of America's news website

Read more from the original source:
Study: Tick Surveillance and Control Lagging in US - Lab Manager Magazine

Cat Litter Box Market 2020 Size, Share, Sales Revenue, Business Trends, Emerging Opportunities, Demand, Key Companies Strategies, New Applications and…

Cat Litter Box Industry 2020 Global Market Research report presents a widespread and elementary study of Cat Litter Box business at the side of the analysis market size, share, trends growth, revenue, production and 2025 forecast. This report also gives you the analytical data of market, like consumption volume, and Cat Litter Box Market price structures throughout the forecast amount from 2020 to 2025.

The report forecast global Cat Litter Box market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2020-2026.The report offers detailed coverage of Cat Litter Box industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Cat Litter Box by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

You Can Get a Sample Copy of this Report at https://www.orianresearch.com/request-sample/1471754

Major Players in Cat Litter Box market are:

The scope of the Global Cat Litter Box Report:

Order a copy of Global Cat Litter Box Market Report @ https://www.orianresearch.com/checkout/1471754

Market by Type

Electric TypeNormal Type

Market by Application

OnlineOffline

Important Aspects of Cat Litter Box Report:

Why To Select This Report:

Complete analysis on market dynamics, market status and competitive Cat Litter Box view is offered.

Forecast Global Cat Litter Box Industry trends will present the market drivers, constraints and growth opportunities.

The five-year forecast view shows how the market is expected to grow in coming years.

All vital Global Cat Litter Box Industry verticals are presented in this study like Product Type, Applications and Geographical Regions.

Table of Contents

Part 1 Market Overview

Part 2 Global Market Status and Future Forecast

Part 3 Asia-Pacific Market Status and Future Forecast

Part 4 Asia-Pacific Market by Geography

Part 5 Europe Market Status and Future Forecast

Part 6 Europe Market by Geography

Part 7 North America Market Status and Future Forecast

Part 8 North America Market by Geography

Part 9 South America Market Status and Future Forecast

Part 10 South America Market by Geography

Part 11 Middle East & Africa Market Status and Future Forecast

Part 12 Middle East & Africa Market by Geography

Part 13 Key Companies

Part 14 Conclusion

Customization Service of the Report:-

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities

About Us:Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US +1 (415) 830-3727| UK +44 020 8144-71-27

Email: [emailprotected]

View post:
Cat Litter Box Market 2020 Size, Share, Sales Revenue, Business Trends, Emerging Opportunities, Demand, Key Companies Strategies, New Applications and...

How Corona Pandemic will Impact Canine Stem Cell Therapy Market Business Opportunity, and Growth 2026 – Cole of Duty

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/15550

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

Here is the original post:
How Corona Pandemic will Impact Canine Stem Cell Therapy Market Business Opportunity, and Growth 2026 - Cole of Duty

Safe to Skip Radiotherapy With Negative PET in Hodgkin Lymphoma – Medscape

The majority of patients with early stage unfavorable Hodgkin lymphoma respond well enough to a current standard regimen of 4 cycles of chemotherapy, and can skip the additional radiotherapy that is normally included in the combined modality treatment, say experts reporting the final results from an international phase 3 randomized trial dubbed HD17.

"Most patients with this disease will not need radiotherapy any longer," concluded first author Peter Borchmann, MD, assistant medical director in the Department of Hematology/Oncology at the University Hospital of Cologne, Germany.

Borchmann was speaking online as part of the virtual edition of the European Hematology Association (EHA) 25th Annual Congress 2020.

"Importantly, the mortality of patients with early stage unfavorable Hodgkin lymphoma in the HD17 study did not differ from the normal healthy German population, and this is the first time we have had this finding in one of our studies," he emphasized.

Borchmann added that positron emission tomography (PET) imaging is key in deciding which patients can skip radiation.

"We conclude from the HD17 trial that the combined modality concept can and should be replaced by a PET-guided omission of radiotherapy for patients with newly diagnosed early stage unfavorable Hodgkin lymphoma," he said.

"The vast majority of early stage unfavorable Hodgkin lymphoma patients can be treated with the brief and highly effective 2+2 chemotherapy alone," he added.

Therefore, he continued, "PET-guided 2+2 chemotherapy is the new standard of care for the German Hodgkin study group," which conducted the trial.

The use of both chemotherapy and radiation has long been a standard approach to treatment, and this combined modality treatment is highly effective, Borchmann explained. But it can cause long-term damage, and the known longer-term negative effects of radiotherapy, such as cardiovascular disease and second malignancies, are a particular concern because patients with early stage Hodgkin lymphoma are relatively young, with a median age of around 30 years at disease onset.

An expert approached for comment said that the momentum to skip radiotherapy when possible is an ongoing issue, and importantly, this study adds to those efforts.

"The treatment of Hodgkin lymphoma has moved for many years now to less radiation therapy, and this trend will continue with the results of this study," commented John G. Gribben, MD, director of the Stem Cell Transplantation Program and medical director of the North East London Cancer Research Network Centre at Barts Cancer Center of Excellence and The London School of Medicine, UK.

"We have moved to lower doses and involved fields with the intent of decreasing toxicity, and particularly long-termtoxicity from radiotherapy," he told Medscape Medical News.

For the multicenter, phase 3 HD17 trial, Borchmann and colleagues turned to PET to identify patients who had and had not responded well to chemotherapy (PET-negative and PET-positive) and to determine if those who had responded well could safely avoid radiotherapy without compromising efficacy.

We wanted to determine if we could reduce the treatment intensity by omission of radiotherapy in patients who respond very well to the systemic treatment, so who have a complete metabolic remission after the chemotherapy, Borchmann said.

The 2+2 treatment approach includes 2 cycles of eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and 2 subsequent cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).

The trial enrolled 1100 patients with newly diagnosed Hodgkin lymphoma between January 2012 and March 2017. Of these, 979 patients had confirmed PET results, with 651 (66.5%) found to be PET-negative, defined as having a Deauville score (DS) of less than 3 (DS3); 238 (24.3%) were DS3 and 90 (9.2%) were DS4.

The study met its primary endpoint of noninferiority in progression-free survival (PFS) at 5 years, with a PFS of 95.1% in the PET-guided group (n = 447) compared with 97.3% in the standard combined-modality treatment group (n = 428), over a median observation time of 45 months, for a difference of 2.2% (P = .12).

"We found that the survival levels were very high and we can safely conclude the noninferiority of the PET-guided approach in PET-negative patients," Borchmann said.

A further analysis showed that the 597 PET-negative patients who did not receive radiotherapy due to their PET status had 5-year PFS that was noninferior to the combined modality group (95.9% vs 97.7%, respectively; P = .20).

And among 646 patients who received the 2+2 regimen plus radiotherapy, of thoseconfirmed as PET-positive (n = 328), the estimated 5-year PFS was significantly lower (94.2%) compared with those determined to be PET-negative (n = 318; 97.6%; hazard ratio, 3.03).

A cut-off of DS4 for positivity was associated with a stronger effect, with a lower estimated 5-year PFS of 81.6% vs 98.8% for DS3 patients and 97.6% for DS < 3 (P < .0001).

"Only DS4 has a prognostic impact, but not DS3," Borchmann said. "DS4 positivity indicates a relevant risk for treatment failure, however, there are few patients in this risk group (9.2% in this trial)."

The 5-year overall survival rates in an intent-to-treat analysis were 98.8% in the standard combined modality group and 98.4% in the PET-guided group.

With a median observation time of 47 months, there have been 10 fatal events in the trial out of 1100 patients, including two Hodgkin lymphoma-related events and one treatment-related death.

"Overall, Hodgkin lymphoma or treatment-related mortality rates were extremely low," Borchmann said.

The study was funded by Deutsche Krebshilfe. Borchmann and Gribben have reported no relevant financial relationships.

EHA 2020 Congress. Presented June 12, 2020. Abstract S101.

For more from Medscape Oncology, join us on Twitter and Facebook.

Read more here:
Safe to Skip Radiotherapy With Negative PET in Hodgkin Lymphoma - Medscape

Shock wave therapy on stem cells focus of lameness research – Horsetalk

Stimulating stem cells to heal faster through the use of shock wave therapy is part of the exciting new research by a Canadian veterinarian.

Dr Judith Koenig, a clinician, researcher and instructor at the Ontario Veterinary College (OVC), is investigating whether shock wave therapy performed after injecting stem cells into a tendon will result in better quality healing. Her research team then came up with the idea of pre-treating stem cells with shock wave prior to injection.

Koenig is also leading a clinical trial, currently enrolling thoroughbred racehorses. The trial performs repeated injection of stem cells that have been harvested from umbilical cord blood, frozen and stored in Dr Thomas Kochs lab. These stem cells are from unrelated horses. Funding from the Ontario Equestrian federation has enabled OVC researchers to also follow a control group treated with platelet-rich plasma as a comparison for this study.

Reduced healing time is an obvious benefit to the welfare of the horse and the horse owner will be pleased about a quicker return to their training rgime.

Lameness is a huge focus for Koenig, who is also a rider with a keen interest in helping grassroots riders and upcoming high-performance athletes.

Realizing many will soon be in the position of starting horses back into training after a significant amount of time off, Koenig offers some important advice.

You need to allow at least a six-week training period for the athletes to be slowly brought back and build up muscle mass and cardiovascular fitness, she says. Both stamina and muscle mass need to be retrained.

She stressed the importance in checking the horses legs for heat and swelling before and after every ride and picking out the feet.A good period of walking is required in the warm-up and cool down and riders need to pay attention to soundness in the walk before commencing their work out.

Koenigs main area of interest in research is tissue healing, particularly wound and tendon healing. She has investigated the use of different modalities (for example shockwave or stem cells) to see if they accelerate tissue healing and which cellular pathways are affected. This will help to direct treatment of tendon injuries and wounds in horses.

Koenig is originally from Austria and moved to Canada 1996 after graduating from vet school to gain research experience and complete the research for her MSc. Following a large animal internship at the Ontario Veterinary College she went to Oregon State University where she did a one-year large animal fellowship. The year in Oregon gave her good exposure to Western Pleasure horses as well as Walking horses, which complemented her previous experience with Sports and Racehorse practice.

She came back to the Ontario Veterinary College where she did a three-year large animal surgery residence with a concurrent graduate degree (DVSc). Koenig became board certified with both the American and European College of Veterinary Surgeons and started to work as faculty in Large Animal Surgery in 2003. Since then she has been working half of the time as a surgeon with a strong interest in Equine Sports Medicine and the other half as researcher and teacher. In 2016, Koenig became a board-certified diplomate for equine sports medicine and rehabilitation.

Excerpt from:
Shock wave therapy on stem cells focus of lameness research - Horsetalk

Bispecific DART Molecule Targeting PD-1, LAG3 Active, Well-Tolerated – Cancer Therapy Advisor

MGD013 is a first-in-class bispecific tetravalent DART molecule designed to bind PD-1 and LAG-3 and restore function of exhausted T cells. Results from a phase 1 study of MGD013 have shown an acceptable safety profile and early activity in patients with advanced solid tumors and hematologic malignancies.

Results of the study were presented by Jason J. Luke, MD, of University of Pittsburgh Hillman Cancer Center in Pennsylvania, during the ASCO20 Virtual Scientific Program.

The study enrolled 50 patients into a dose escalation study from 1 mg to 1200 mg every 2 weeks, and 157 patients into a cohort expansion study at the phase 2 dose of 600 mg.

About 70% of patients experienced a treatment-related adverse event, with 23.2% experiencing grade 3 or worse events. The most commonly reported adverse events were fatigue (19%) and nausea (11%).

Among the patients in the dose escalation cohort who were evaluable for response there were 3 confirmed partial responses. One occurred in a patient with triple-negative breast cancer, 1 in a patient with mesothelioma, and 1 in a patient with gastric cancer. Eighteen patients had stable disease. This resulted in a disease control rate of 48.8%.

Dr Luke note that several cohorts in the study are ongoing, including a lymphoma cohort. He highlighted 1 patient from that cohort, a 27-year-old man with diffuse large B-cell lymphoma who had progression of disease after CAR-T cell therapy. This patient was given a single dose of MGD013 at 600 mg.

A pretreatment biopsy from the patients lymph node showed high expression of PD-1 and LAG-3. After CAR-T, the patient had CD19 loss. After his dose of MGD013, the patient was admitted to the hospital on day 11 due to grade 2 cytokine release syndrome, but had a complete response on PET scan at day 24. The patient later had allogeneic stem cell transplant and is now in remission 11 months post-MGD103.

Evaluation of MGD103 as monotherapy and in combination with FC-engineered monoclonal antibodies such as margetuximab is going, Dr Luke concluded.

Read more of Cancer Therapy Advisors coverage of the ASCO 2020 meeting by visiting the conference page.

Reference

Luke JJ, Patel MR, Hamilton EP, et al. A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecular binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms. Presented at: ASCO20 Virtual Scientific Program.J Clin Oncol. 2020;38(suppl):abstr 8001.

Continued here:
Bispecific DART Molecule Targeting PD-1, LAG3 Active, Well-Tolerated - Cancer Therapy Advisor

Back to Top